Switch theme
Sign up to access all valuation multiples
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
2010
80
LTM Revenue $15.2M
Last FY EBITDA -$126M
$372M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Verastem has a last 12-month revenue (LTM) of $15.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Verastem achieved revenue of $10.0M and an EBITDA of -$126M.
Verastem expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Verastem valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $15.2M | XXX | $10.0M | XXX | XXX | XXX |
| Gross Profit | $13.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$126M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1259% | XXX | XXX | XXX |
| EBIT | -$131M | XXX | -$115M | XXX | XXX | XXX |
| EBIT Margin | -864% | XXX | -1150% | XXX | XXX | XXX |
| Net Profit | -$140M | XXX | -$131M | XXX | XXX | XXX |
| Net Margin | -927% | XXX | -1306% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Verastem's stock price is $8.
Verastem has current market cap of $413M, and EV of $372M.
See Verastem trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $372M | $413M | XXX | XXX | XXX | XXX | $-3.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Verastem has market cap of $413M and EV of $372M.
Verastem's trades at 37.2x EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate Verastem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Verastem has a P/E ratio of -2.9x.
See valuation multiples for Verastem and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $413M | XXX | $413M | XXX | XXX | XXX |
| EV (current) | $372M | XXX | $372M | XXX | XXX | XXX |
| EV/Revenue | 24.5x | XXX | 37.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -2.8x | XXX | -3.2x | XXX | XXX | XXX |
| EV/Gross Profit | 27.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.9x | XXX | -3.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVerastem's last 12 month revenue growth is 236%
Verastem's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.6M for the same period.
Verastem's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Verastem's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Verastem and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 236% | XXX | 202% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1259% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -1023% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 813% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1250% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Verastem acquired XXX companies to date.
Last acquisition by Verastem was XXXXXXXX, XXXXX XXXXX XXXXXX . Verastem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Verastem founded? | Verastem was founded in 2010. |
| Where is Verastem headquartered? | Verastem is headquartered in United States of America. |
| How many employees does Verastem have? | As of today, Verastem has 80 employees. |
| Who is the CEO of Verastem? | Verastem's CEO is Mr. Daniel Paterson. |
| Is Verastem publicy listed? | Yes, Verastem is a public company listed on NAS. |
| What is the stock symbol of Verastem? | Verastem trades under VSTM ticker. |
| When did Verastem go public? | Verastem went public in 2012. |
| Who are competitors of Verastem? | Similar companies to Verastem include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Verastem? | Verastem's current market cap is $413M |
| What is the current revenue of Verastem? | Verastem's last 12 months revenue is $15.2M. |
| What is the current revenue growth of Verastem? | Verastem revenue growth (NTM/LTM) is 236%. |
| What is the current EV/Revenue multiple of Verastem? | Current revenue multiple of Verastem is 24.5x. |
| Is Verastem profitable? | Yes, Verastem is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
